Literature DB >> 16203510

Cannabis use and psychosis.

W Hall1.   

Abstract

This paper reviews evidence on two hypotheses about the relationship between cannabis use and psychosis. The first hypothesis is that heavy cannabis use may cause a "cannabis psychosis"-a psychosis that would not occur in the absence of cannabis use, the symptoms of which are preceded by heavy cannabis use and remit after abstinence. The second hypothesis is that cannabis use may precipitate schizophrenia, or exacerbate its symptoms. Evaluation of these hypotheses requires evidence of an association between cannabis use and psychosis, that is unlikely to be due to chance, in which cannabis use precedes psychosis, and in which we can exclude the hypothesis that the relationship is due to other factors, such as other drug use, or a personal vulnerability to psychosis. There is some clinical support for the first hypothesis. If these disorders exist they seem to be rare, because they require very high doses of THC, the prolonged use of highly potent forms of cannabis, or a pre-existing (but as yet unspecified) vulnerability. There is more support for the second hypothesis, in that a large prospective study has shown a linear relationship between the frequency with which cannabis has been used by age 18 and the risks over the subsequent 15 years of a diagnosis of schizophrenia. It is still unclear whether this means that cannabis use precipitates schizophrenia, whether it is a form of "self-medication", or whether the association is due to the use of other drugs, such as amphetamines, which heavy cannabis users are more likely to use. There is stronger evidence that cannabis use can exacerbate the symptoms of schizophrenia. Mental health services should identify patients with schizophrenia who use alcohol, cannabis and other drugs and advise them to abstain or to greatly reduce their drug use.

Entities:  

Year:  1998        PMID: 16203510     DOI: 10.1080/09595239800187271

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  22 in total

Review 1.  Improving the quality of the cannabis debate: defining the different domains.

Authors:  J Strang; J Witton; W Hall
Journal:  BMJ       Date:  2000-01-08

2.  The cannabis policy debate: finding a way forward.

Authors:  W Hall
Journal:  CMAJ       Date:  2000-06-13       Impact factor: 8.262

Review 3.  Cannabis and psychosis.

Authors:  Louisa Degenhardt; Wayne Hall
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

4.  The at-risk adolescent marijuana nonuser: expanding the standard distinction.

Authors:  William D Crano; Jason T Siegel; Eusebio M Alvaro; Andrew Lac; Vanessa Hemovich
Journal:  Prev Sci       Date:  2008-05-31

Review 5.  Cannabis-associated psychosis: current status of research.

Authors:  F Markus Leweke; Christoph W Gerth; Joachim Klosterkötter
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  Cannabis use and the risk of developing a psychotic disorder.

Authors:  Wayne Hall; Louisa Degenhardt
Journal:  World Psychiatry       Date:  2008       Impact factor: 49.548

Review 7.  Role of cannabis and endocannabinoids in the genesis of schizophrenia.

Authors:  Emilio Fernandez-Espejo; Maria-Paz Viveros; Luis Núñez; Bart A Ellenbroek; Fernando Rodriguez de Fonseca
Journal:  Psychopharmacology (Berl)       Date:  2009-07-24       Impact factor: 4.530

8.  Cannabis use and mental health in young people: cohort study.

Authors:  George C Patton; Carolyn Coffey; John B Carlin; Louisa Degenhardt; Michael Lynskey; Wayne Hall
Journal:  BMJ       Date:  2002-11-23

9.  Cannabis-induced bipolar disorder with psychotic features: a case report.

Authors:  Masood A Khan; Sailaja Akella
Journal:  Psychiatry (Edgmont)       Date:  2009-12

10.  Should burden of disease estimates include cannabis use as a risk factor for psychosis?

Authors:  Louisa Degenhardt; Wayne D Hall; Michael Lynskey; John McGrath; Jennifer McLaren; Bianca Calabria; Harvey Whiteford; Theo Vos
Journal:  PLoS Med       Date:  2009-09-29       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.